natgillin/translations-raw huggingface dataset:
WO 2004/063209 discloses methods of producing C-aryl glucoside SGLT2 inhibitors having the following structure: In a preferred embodiment, the processes of WO 2004/063209 enable the synthesis of compounds having the following structure: wherein 1) R1 is hydrogen and R2 is ethyl; 2) R1 is chlorine and R2 is ethoxy; or 3) R1 is methyl and R2 is methylthio. 
WO 2004/063209 opisuje postupke za proizvodnju C-aril glukozid SGLT2 inhibitora koji imaju slijedeću strukturu: (Ra R gdje 1) Ry je vodik i R> je etil; 2) Ri je klor i R> je etoksi; ili 3) Ry je metili R, je metiltio.
at least 15 µg compound of formula (1)/kg/minute. 
(e) najmanje 15 ug spoja sa formulama (1) ili (2)/kg/minuti.
A composition comprising a pharmaceutically acceptable carrier and GLA for use in a method of treating an allergic condition in a subject, wherein the GLA has the formula: wherein: 
Sastav koji sadrži farmaceutski prihvatljivi nosač i glukopiranozilni lipidni adjuvans (GLA) za uporabu u metodi liječenja alergiskog stanja kod subjekta;
A method of controlling undesired vegetation, which comprises applying a synergistic herbicidal mixture as claimed in any of claims 1 or 2 before, during and/or after the emergence of undesired plants simultaneously or in succession. 
Postupak kontrole neželjene vegetacije, a koji obuhvaća primjenu sinergijske herbicidne smjese prema bilo kojem od prethodnih zahtjeva 1 do 2, prije, tijekom i/ili nakon pojave neželjenih biljaka istodobno ili uzastopno.
The method according to any one of claims 8 to 13, wherein the antibody has at least one N-glycosylation site having the amino acid sequence Asn-Xaa-Ser/Thr, wherein Xaa can be any amino acid except Pro, and/or at least one O-glycosylation site in the sequence of the Fab region. 
Pripravak s molekulom protutijela u skladu s bilo kojim od patentnih zahtjeva 19 do 27, naznačen time što protutijelo ima najmanje jedno mjesto N-glikoziliranja čiji je aminokiselinski slijed Asn-Xaa-Ser/Thr, gdje Xaa može biti bilo koja aminokiselina osim Pro, i/ili najmanje jedno mjesto O-glikoziliranja u slijedu područja Fab.
The compound for use according to Claim 6, wherein said additional therapeutic agent is selected from the group consisting of benzodiazepines, and antipsychotics. 
Spoj za uporabu prema zahtjevu 6, naznačen time da se navedeno dodatno terapijsko sredstvo bira iz skupine koju čine benzodiazepini, te antipsihotici.
Cell pellets were resuspended in harvest buffer (20 mM HEPES, 10 mM EDTA, pH 7.4) and homogenized with 4 X 10 second bursts of a 12 mm Polytron homogenizer, setting 5. 
Pelete stanica su resuspendirane u puferu za skupljanje (20 mM EPES, 10 mM EDTA, pH 7,4) i homogenizirane sa 4 X 10 drugog sredstva za razgradnju od 12 mm Polytron homogenizatora, položaj 5.
express one or more genes at a detectably higher level than an equivalent number of bone marrow derived mesenchymal stem cells, wherein said one or more genes comprise one or more of BMP4, BMP6, CD36, CDH11, COL14A1, COL15A1, COL1A1, COL3A1, COLSA1, CSF2, CTSK, FGF2, FGFR1, FLT1, ITGA1, MINPP1, MMP9, MSX1, PDGFA,SERPINH1, TGFB3 and TGFBR1, wherein said OPACs and said mesenchymal stem cells have undergone an equivalent number of passages; or express one or more genes at a detectably higher level than an equivalent number of fibroblast cells, wherein said one or more genes comprise one or more of BMP4, BMP6, CDH11, COL14A1, COL15A1, COL1A1, COL3A1, COL5A1, FLT1, IGF1R, ITGA1, MINPP1, PDGFA, SERPINH1, SMAD3, TGFB1, TGFB2, TGFB3, TGFBR1, TNF, TUFT1, VCAM1 and VEGFA, and wherein said fibroblast cells have undergone an equivalent number of passages. 
Izolirani OPAC, namijenjeni upotrebi u skladu s patentnim zahtjevom 1, naznačeni time što navedeni OPAC: eksprimiraju jedan ili više gena na mjerljivo višoj razini nego odgovarajući broj mezenhimnih matičnih stanica iz koštane srži, gdje navedeni jedan ili više gena uključuju jedan ili više od BMP4, BMP6, CD36, CDH11, COLI4AIJ, COL1S5A1, COLIA1l, COL3A1, COLSA1, CSF2, CTSK, FGF2, FGFRI, FLTI, ITGA1, MINPP1, MMP9, MSCI, PDGFA, SERPINH1, TGFB3 i TGFBRI1, gdje su navedeni OPAC i navedene mezenhimne matične stanice prošli ekvivalentan broj pasaža; ili eksprimiraju jedan ili više gena na mjerljivo višoj razini nego odgovarajući broj fibroblasta, gdje navedeni jedan ili više gena uključuju jedan ili više od BMP4, BMP6, CDH11, COLI4A1, COLISA1, COLIA1, COL3A1, COLSAI, FLTI, IGFIR, ITGA1, MINPPI, PDGFA, SERPINHI1, SMAD3, TGFB1, TGFB2, TGFB3, TGFBRI, TNF, TUFT1, VCAMI i VEGFA, te gdje su navedeni OPAC 1 navedeni fibroblasti prošli ekvivalentan broj pasaža.
The method according to claim 1, wherein the A SMSC measures the time elapsed from sending an alert message to an MSISDN number through connected cell to receiving a confirmation from the cell, and if the time elapsed is above a certain limit, the MDC will reduce a load of the current cell by sending the next alert message through another cell. 
Postupak prema zahtjevu 1, naznačen time da A-SMSC (30) mjeri vrijeme koje je proteklo od slanja poruke upozorenja prema MSISDN broju preko njegove stanice na koju je spojen do prijema potvrde od stanice, te ako je proteklo vrijeme iznad određene granice, MDC (30) će smanjiti opterećenje trenutne stanice slanjem slijedeće poruke upozorenja putem druge stanice.
the HA is in an amount of about 0.1%; or 
količina HA iznosi približno 0,1%; ili
The cutting elements are generally flat members that may have sharpened edges, pointed tips, and one or more bends along the surface of the cutting elements. 
Rezači su obično plosnati dijelovi koji mogu imati naoštrene rubove, zašiljene vrhove te jednu ili više krivina duž površine rezača.
Dosage forms preferred according to the invention for parenteral administration contain from 0.005 mg to 5 mg of roflumilast, preferably from 0.01 mg to 2.5 mg, particularly preferably 0.1 mg to 0.5 mg of roflumilast per dosage unit. 
Povoljni dozimi oblici prema izumu za parenteralnu primjenu sadrže od 0.005 mg do 5 mg roflumilasta, povoljnije od 0.01 mg do 2.5 mg, te posebno povoljno od 0.1 mg do 0.5 mg roflumilasta po dozirnoj jedinici.
A method of producing a heavy chain-only antibody which binds specifically to an antigen comprising: 
Postupak dobivanja topive Vgq domene ili Vu fuzijskog proteina koji se specifično veže na antigen koji sadrži:
is H; Q3; or C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 alkylcycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with one or more substituents independently selected from R7; or R11 and R12 are taken together with the nitrogen to which they are attached to form a ring containing 2 to 6 atoms of carbon and optionally one additional atom selected from the group consisting of N, S and O, said ring optionally substituted with 1 to 4 substituents independently selected from the group consisting of C1-C2 alkyl, halogen, -CN, -NO2 and C1-C2 alkoxy; 
je H; Q3; ili C1-C6 alkil, C2-C6 alkenil, C2-C6 alkinil, C3-C6 cikloalkil, C4-C7 alkilcikloalkil ili C4-C7 cikloalkilalkil, svaki opcijski supstituiran jednim ili više supstituenata odabranih od R7; ili i R12 zajedno sa dušikom za koji su vezani formiraju prsten koji sadrži 2 do 6 atoma ugljika i opcijski jedan dodatni atom odabran iz grupe koja sadrži N, S i O, spomenuti prsten je opcijski supstituiran sa 1 do 4 supstituenta odabrana iz grupe koja se sastoji od C1-C2 alkil, halogen, -CN, -NO2 i C1-C2 alkoksi;
The recombinant RhCMV or HCMV vector of any one of claims 1-11, or the composition of claim 12 for use in a method of treating a subject with an infectious disease, or at risk of becoming infected with an infectious disease, or with cancer, or at risk of developing cancer. 
Rekombinantni vektor RRCMYV ili HCMV u skladu s bilo kojim od patentnih zahtjeva 1-11, ili pripravak u skladu s patentnim zahtjevom 12, naznačen time što je namijenjen upotrebi u postupku liječenja subjekta sa zaraznom bolešću, ili je u opasnosti od zaražavanja zaraznom bolešću, ili s rakom, ili je u opasnosti od razvoja raka.
The combined chloroform layers were dried over anhydrous magnesium sulphate and after filtration the solvent was removed at reduced pressure to give a brown oil (14.35 g, yield > 100% probable solvent remain in product). 
Spojeni slojevi kloroforma se suše iznad anhidridnog magnezij sulfata i nakon filtriranja otapalo se ukloni uz smanjeni tlak dajući smeđe ulje (14.35 g, prinos > 100% - vjerojatno od zaostalog otapala u produktu).
The method according to claim 1, wherein the transfected cells obtained in step b) are cloned. The method of claim 4, wherein the cells are cloned using FACS cloning. The method of claim 4, wherein clones are selected for at least one criterion selected from the group consisting of: growth rate, doubling time, expression level, production level, stability of production over time, viability, hardiness, robustness, morphology, and copy number. 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što transficirane stanice, dobivene u koraku b), se klonira, primjerice putem FACS kloniranja, a po mogućnosti kada se klonove bira za najmanje jedan kriterij, kojeg se bira iz skupine koju čine brzina rasta, vrijeme udvostručavanja, razina ekspresije, razina proizvodnje, stabilnost proizvodnje u vremenu, vijabilnost, izdržljivost, robustnost, morfologija i broj kopija.
In addition, drug substance with high polymorph purity could not be obtained by micronization of the monoclinic form of asenapine maleate. 
Dodatno, ljekovita tvar s visokom polimorfnom čistoćom nije se mogla dobiti mikronizacijom monoklinskog oblika asenapin maleata.
first sensing means connected for signal communication with said monitoring and control unit and suitable for detecting and acquiring at preset time intervals AT a value of a first pressure PT 1 in said return circuit; 
prva osjetna sredstva (22) povezana radi signalne veze sa navedenom nadzornom i kontrolnom jedinicom (21) koja su pogodna za otkrivanje i dobivanje u unaprijed određenim vremenskim intervalima AT vrijednosti prvog tlaka PTI u navedenom povratnom krugu (14);
It is noted that different techniques for determining the content of high molecular components may yield different results. 
Treba primijetiti da različite tehnike za određivanje sadržaja komponenata s velikom molekulskom masom mogu dati različite rezultate.
The formulation according to claim 10 or 11, comprising the polyethylene-polypropylene glycol in a concentration ranging from 0.5 to 5 mg/ml or 1 to 2 mg/ml or 1.5 mg/ml. 
Formulacija prema zahtjevu 10 ili 11, naznačena time da sadrži polietilen-polipropilen glikol u koncentraciji u rasponu od 0,5 do 5 mg/mlili 1 do 2 mg/mlili 1,5 mg/ml.
A composition comprising recombinant Von Willebrand Factor (rVWF) having a specific ristocetin cofactor activity of at least 40 mU/µg. The composition according to claim 11, wherein the specific Ristocetin cofactor activity is from 50 to 100 mU/µg. 
Pripravak koji sadrži rekombinantni Von Willebrand faktor (rVWF) koji ima specifičnu kofaktornu aktivnost ristocetina od najmanje 80 mU/µg, pri čemu se pripravak može dobiti postupkom koji sadrži sljedeće korake:
The method of claim 1, wherein the antisense oligonucleotide does not activate RNase H. 
Antisens oligonukleotid u skladu sa zahtjevom 1, naznačen time što navedeni antisens oligonukleotid ne aktivira RNazu H.
a data stream stored in the non-transitory computer-readable medium, the data stream comprising an encoded significance map indicating positions of significant transform coefficients within a transform coefficient block, and the significant transform coefficients within the transform coefficient block, 
Postupak za dekodiranje signifikacijske mape iz protoka podataka, koja prikazuje pozicije signifikantnih koeficijenata transformacije unutar bloka koeficijenata transformacije, naznačen time, da taj postupak obuhvaća sljedeće:
Compounds in the present invention may also be useful in treating diseases associated with dysfunction of brain dopaminergic systems, such as Parkinson's Disease and substance abuse disorders. 
Spojevi u prikazanom izumu mogu također koristiti u liječenju bolesti u vezi sa disfunkcijom moždanog dopaminergijskog sustava, kao što su Parkinsonova bolest i poremećaj i zloupotrebe tvari.
represents a -CR14 group and G2 represents a nitrogen atom, or G1 represents a nitrogen atom and G2 represents a -CR15 group, or G1 represents a -CR14 group and G2 represents a -CR15 group; 
predstavlja -CR14 grupu, a G2 predstavlja atom dušika, ili G1 predstavlja atom dušika, a G2 predstavlja -CR15 grupu, ili G1 predstavlja -CR14 grupu, a G2 predstavlja -CR15 grupu;
The compound of claim 1, wherein the compound of Formula I is represented by compound selected from the group consisting of: 
Spoj iz patentnog zahtjeva 1, gdje se spoj odabran iz grupe sastoji od:
The method according to claim 12, wherein the coagulation is carried out in closed tanks for 2-10 hours, constantly using gentle stirring. 
Postupak prema zahtjevu 6, naznačeno time da je koauglacija provedena u zatvorenim spremnicima kroz 2 do 10 sati, uz nesprestano lagano mješanje.
Preferably the flavoring agent is selected from the group consisting of natural flavors, natural fruit flavors, artificial flavors, artificial fruit flavors, peppermint, peppermint oils and mixtures thereof. 
Formulacija zahtjeva 1 gdje je korigens okusa izabran iz grupe koju čine višnja, grožđe, jagoda, crvena naranča, lubenica, banana, citrus vanilija i njihove smjese.
subjecting the compound of formula (9) to catalytic hydrogenation to remove the protecting groups PG and, when R4' is C2-5 alkenyl, reduce the group R4' to C2-5 alkyl; and thereafter, where the compound of formula (6) is prepared in the form of a free base, optionally converting the free base to an acid addition salt. 
(b) podvrgavanje spoja formule (9) katalitičkoj hidrogenaciji radi uklanjanja zaštitnih skupina PG i, kada R* označava C>.s alkenil, reduciranja skupine R" na C,.s alkil; i nakon toga, gdje se spoj formule (6) pripravlja u obliku slobodne baze, izborno pretvaranja slobodne baze u kiselinsku adicijsku sol.
wherein in groups (1) to (3) any alkyl group may be optionally substituted with one or more halogen groups and the C3-8 cycloalkyl group may be optionally substituted with one or more substituents independently selected from C1-4 alkyl, halogen and aryl; 
(3) aril-C,g alkil; pri čemu u skupinama (1) do (3) bilo koja alkilna skupina po izboru može biti supstituirana s jednom ili više skupina halogena, a C3.s cikloalkilna skupina po izboru može biti supstituirana s jednim ili više supstituenata 15
When the compound of general formula (II) acts as a prodrug, it is later transformed to the drug by the action of an esterase in the blood or in a tissue of the patient. 
Postupak za pripremu spoja prema patentnom zahtjevu 1, naznačen time što sadrži hidrolizu spoja prema patentnom zahtjevu 2 sa bazom.
The present invention further provides a process as described above, characterized in that an ester of the formula (IVa) is prepared by cyclization of the 5-aminopyrazole derivative (IIa) 
2. | Postupak prema zahtjevu 1, naznačen time što se ester s formulom (IVa) priprema pomoću ciklizacije derivata 5-aminopirazola s formulom 15 (IIa) pd
Reinforced Building block according to at least one of the preceding claims, characterized in that latent hardeners selected from dicyandiamide, cyanoguanidines, aromatic amines, guanidines, modified polyamines, N-acylimidazoles, imidazoles, carbonyl hydrazides, triazine derivatives, melamine and derivatives thereof, N-cyanoacylamide compounds, acylthiopropylphenolsare used. 
Armirani građevni blok prema najmanje jednom od prethodnih patentnih zahtjeva, naznačen time što se koriste latentni učvršćivači odabrani od dicijanidamida, cijanogvanidina, aromatskih amina, gvanidina, modificiranih poliamina, N-acilimidazola, imidazola, karbonil hidrazida, derivata triazina, melamina i njegovih derivata, spojeva N-cijanoacilamida, aciltiopropilfenolzara.
(a10) an antigen-binding site comprising an H chain CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 102, 103, and 104 (H chain CDRs of Q460), respectively; 
(alO)mjesto vezanja antigena koje obuhvaća aminokiselinske sekvence H-lanca CDR-područja 1, 213 od SEQ ID NO: 102, 103 odnosno 104 (H-lanac CDR-područja od Q460);
The vaccine of claim 11 wherein the immunogenic composition contains a protein of SEQ ID NO: 69, Protein D and a PE-PilA fusion protein, optionally LVL-735. 
Cjepivo u skladu s patentnim zahtjevom 11, naznačeno time što imunogeni pripravak sadrži protein sa SEQ ID NO: 69, Protein D i fuzijski protein PE-P1lA, izborno LVL-735.
the recovery of said antibodies, or one of their functional fragments, thus produced starting from the culture medium or said cultured cells. 
izolaciju rečenih antitijela ili jednog od njegovih divalentnih fragmenata koji se vežu na c-Met iz medija za kulturu ili rečenih kultiviranih stanica.
coupling a compound of formula (XVIII): or an acid addition salt thereof, with a compound of formula (XIX): wherein: 
spajanja spojaformule (XVIII): [image] ili njegove kisele adicijske soli, sa spojem formule (XIX):
At least one antigen binding protein of any one of claims 1-5 for use in therapy, wherein said antigen binding protein reduces IL-23 activity in a patient and wherein said IL-23 activity is inducing production of a proinflammatroy cytokine. 
Najmanje jedan protein koji veže antigen iz bilo kojeg od patentnih zahtjeva 1-5 za uporabu u liječenju, pri čemu navedeni protein koji veže antigen smanjuje aktivnost IL-23 u pacijenta 1 pri čemu navedena aktivnost IL-23 potiče stvaranje proupalnih citokina.
A biofertilizer composition being prepared before use by combining a bacterial suspension and a polysaccharide solution, wherein said bacterial suspension consists of Pseudomonas antarctica DaBact TI-9, Pseudomonas trivialis DaBact 2H and Arthrobacter ssp. 
Smjesa bio gnojiva koja se priprema prije uporabe kombinirajući jednu bakterijsku suspenziju i jednu otopinu polisaharida, naznačena time da se ta bakterijska suspenzija sastoji od sojeva bakterija Pseudomonas antarctica DaBact TI-9, Pseudomonas trivialis DaBact 2H 1 Arthrobacter ssp.
Stabilisation of microwave heated food substrates 
STABILIZACIJA PREHRAMBENIH SUPSTRATA KOJI SE ZAGRIJAVAJU U MIKROVALNOJ
A method according to any preceding claim, wherein the sheet-form material includes one or more of carbon fibres, glass fibres and aramid fibres. 
Postupak prema zahtjevu 10, naznačen time, da pločasti materijal obuhvaća jedno ili više ugljičnih vlakana, staklenih vlakana i aramidnih vlakana.
The reaction mixture is poured onto water (600 ml) and extracted with 1:1 ethyl acetate/diethyl ether (4 x 300 ml). 
Reakcijsku smjesu se prelije na vodu (600 ml) i ekstrahira s 1:1 etil acetat/dietil eterom (4 x 300 ml).
The composition for use according to any preceding claim, wherein the at least one C1 esterase inhibitor is isolated or purified from human plasma or is recombinantly produced, and/or wherein the C1 esterase inhibitor has an amino acid sequence at least 90%, 95%, 98%, 99% or 100% identical to the human C1 esterase inhibitor amino acid sequence of Figure 1. 
Pripravak za upotrebu prema bilo kojem prethodnom zahtjevu, naznačen time da je najmanje jedan inhibitor C1 esteraze izoliran ili pročišćen iz ljudske plazme ili je dobiven pomoću tehnika rekombinacije, i/ili pri čemu inhibitor C1 esteraze ima sekvencu amino kiselina 90%, 95%, 98%, 99% ili 100% identičnu s ljudskom sekvencom amino kiselina inhibitora C1 esteraze na slici 1.
Soil (10) as claimed in claim 5, wherein said sandy material of said upper layer (7) consists of crushed stones and sand having pH values included between 6.0 and 7.5. 
Mješoviti travnjak (1) prema zahtjevima 5 ili 6, naznačen time da navedeni pjeskoviti materijal u navedenom gornjem sloju (7) je drobljeni kamen i pijesak pH vrijednosti od 6,0 do 7,5.
wherein R6 is hydrogen, halogen, benzyloxy or phenoxy, phenyl, pyrazole, C3-C6 cycloalkyl, optionally substituted with halogen, preferably substituted with fluoro. 
NK i i gdje R5 jest vodik, halogen, benziloksi ili fenoksi, fenil, pirazol, Cs-C4 cikloalkil, koji može biti supstituiran halogenom, preferirano supstituiran fluorom.
1,2-dipalmitoyl- sn -glycero-3-phosphocholine (DPPC) and 1-palmitoyl-2-oleyl- sn -glycero-3-phosphoglycerol (POPG) in a weight ratio of about 50:50; all the amounts being calculated relative to the total weight of the reconstituted surfactant. 
1,2-dipalmitoil-sn-glicero-3-fosfokolin (DPPC) i 1-palmitoil-2-oleil-sn-glicero-3-fosfoglicerol (POPG) u omjeru masa od oko 50:50; sve su količine izračunate relativno prema ukupnoj masi rekonstituiranog surfaktanta.
The process of claim 1 or 2, wherein the gelling agent consists of gelatin. 
Proces iz patentnog zahtjeva I ili 2, gdje agens za geliranje se sastoji od želatina.
The method of claim 41, wherein the chemotherapeutic agent is selected from the group consisting of doxorubicin, cisplatin, taxotere, 5-fluorouracil, methotrexate, gemcitabine, and cyclophosphamide. 
Protutijelo, konjugat ili farmaceutski pripravak za uporabu sukladno patentnom zahtjevu 8, naznačeno time, što kemoterapeutsko sredstvo je odabrano iz skupine koja se sastoji od doksorubicina, cisplatina, taksotere, 5fluoruracila, metotreksata, gemcitabine i ciklofosfamida.
Of course, damaged inoculant cells can inhibit or destroy their efficacy. 
Svakako postoji mogućnost da oštećene stanice inokulanta umanjuju ili gube svoju učinkovitost.
The method of claim 2, wherein the compound is represented by the following structural formula: 
Spoj prema zahtjevu 19, pri čemu je spoj prikazan slijedećom strukturnom formulom: a
The molecule of claim 25, wherein the activated B chain has a conformation of B chain obtained by cleavage of single chain HGF. 
Molekula prema zahtjevu 25, naznačena time, da aktivirani B lanac ima konformaciju B lanca dobivenog cijepanjem jednolančanog HGF.
The method according to claim 9, wherein the influenza virus strain is selected from the group consisting of H1N1, H5N1, H5N2, H5N8, H5N9, an H2-based strain, and H9N2. 
Antitijelo, ili njegov dio koji veže antigen, prema zahtjevu 6, naznačeni time da je navedeni soj virusa influence koji je povezan sa izbijanjem pandemije odabran iz skupine koja sadrži: HIN1, HSN1, H5N2, HSN8, HSN9, soj na osnovi H2, i H9N2.
A pharmaceutical composition comprising a therapeutically effective amount of a salt according to any one of claims 1 or 2 and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak koji sadrži terapeutski učinkovitu količinu soli u skladu sa zahtjevom 1 ili 2 1 farmaceutski prihvatljiv nosač.
The residue was purified by flash chromatography using 30% ethyl acetate-hexanes to give a 1:1 mixture of the C-5 and C-6 alcohols. 
Ostatak se pročisti na svjetlosnom kromatografijom uporabom 30% etil acetat-heksana da bi se dobila smjesa 1:1 C-5 i C-6 alkohola.
The composition of claim 17 wherein said B-cyclodextrin is hydroxypropyl B-cyclodextrin, or sulfobutylether B-cyclodextrin. The composition of claim 16 wherein said pharmaceutically acceptable salt is a hydrochloride salt, methanesulfonate, toluenesulfonate, acetate, succinate, citrate, maleate, tartrate, or mixtures thereof. 
Sastav prema zahtjevu 11, naznačeno time da je spomenuta farmaceutski prihvatljiva sol hidrokloridna sol, metan sulfonat, toluensulfonat, acetat, sukcinat, citrat, maleat, tartrat, ili mješavina istih, poželjno sol acetata.
A device according to claim 8, characterized in that said feeding means (13-15) is configured to feed a coating mass in the form of a glass flake or glass fiber reinforced polyester to said mixing casing (12). 
Naprava u skladu s patentnim zahtjevom 6, naznačena time, da su navedeni dovodni sklopovi (13 - 15) konfigurirani tako da dovode masu za premazivanje u obliku staklene pogače ili poliestera ojačanog staklenim vlaknima u navedeno kućište za miješanje (12).
a fuel gas supply line (L1) configured to extract LNG from the LNG tank and supply the extracted LNG as fuel gas to the high-pressure gas injection engine; 
drugu crpku (4) konfiguriranu da dodatno stlačuje LNG na visoki pritisak i da dobavlja dodatno komprimirani LNG prema visokotlačnom plinskom injekcijskom motoru;